1 **Estimation of SARS-CoV-2 emissions from non-symptomatic cases**

2 A.A.Prof. Dr. Michael Riediker[1], Dr. Dai-Hua Tsai[1,2]

3 1 Swiss Centre for Occupational and Environmental Health, Winterthur, Switzerland

4 2 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of

5 Psychiatry Zurich, University of Zurich, Zurich, Switzerland

6 Key Points

Question: How much SARS-CoV-2 virus is released from a case by breathing and coughing,

and what is the resulting concentration in a room?

Finding: Both, breathing and coughing are predicted to release large numbers of viruses,

which can lead to billions of virus copies/m^3 in a poorly ventilated room with a coughing

emitter.

Meaning: These results may explain the high rate of transmissions and implies the need for

strict respiratory protection when people are in the same room with a COVID-19 case.

14 Word counts:

15 Abstract: 272, Manuscript: 1801, Tables: 1, Figures: 3

16 Address for correspondence

17 Michael Riediker

18 michael.riediker@alumni.ethz.ch

19 Swiss Centre for Occupational and Environmental Health (SCOEH)

20 Binzhofstrasse 87, CH-8404 Winterthur, Switzerland

Abstract

Importance: Cases of the coronavirus disease 2019 (COVID-19) with no or mild symptoms were reported to frequently transmit the disease even without direct contact. The severe acute respiratory syndrome virus (SARS-COV-2) was found at very high concentrations in swab and sputum of such cases.

Objective: We aimed to estimate virus release from such cases into different aerosol sizes by normal breathing and coughing, and what exposure can result from this in a room shared with such as case.

Data Sources and Model: We combined the size-distribution of exhaled breath aerosols for coughing and normal breathing with viral sputum concentrations as approximation for lung lining liquid to obtain an estimate of emitted virus levels. The resulting emission data fed a single-compartment model of airborne concentrations in a room of 50m^3, the size of a small office or medical exam room.

Results: The estimated viral load in aerosols emitted by patients while breathing normally was on average 0.34 copies/cm^3 and could go up to 11.5 copies/cm^3. The corresponding numbers for coughing patients were 10,900 copies/cm^3 and 366,000 copies/cm^3, respectively, per cough. The resulting concentrations in a room with a coughing emitter were always very high, up to 2.02*10^9 copies/m^3. However, also regular breathing aerosol from high emitters was predicted to lead to several thousand copies/m^3.

Conclusions and Relevance: These very high predicted virus concentrations may provide an explanation why for COVID-19, frequent community transmissions from non-symptomatic cases and also high infection rates in medical staff in hospital settings were reported. Our findings suggest that strict respiratory protection is needed when there is a chance to be in

44 the same room with a patient - whether symptomatic or not - especially if this was for a

45 prolonged time.

Introduction

The novel Coronavirus disease 2019 (COVID-19), emerged in late 2019 in Wuhan, China [1]

from where it spread to the entire world. COVID-19 is caused by a novel type of Coronavirus,

the severe acute respiratory syndrome virus (SARS-COV-2) [2]. The host-receptor for SARS-

CoV-2 was found to be Angiotensin I converting enzyme 2 (ACE2), which is present in cells of

the lungs and airways [3]. A large number of patients hospitalized for other reasons and also

an important proportion of the medical staff contracted COVID-19 [4]. This is remarkable given

that medical professionals are trained at protecting themselves against infections. Also a

series of community-transmissions were reported from cases that had no apparent

symptoms, some even without direct contact [5–8]. Correspondences about the viral load in

samples from COVID-19 patients having no or only mild symptoms reported very high

concentrations of SARS-CoV-2 in swab samples [8–10]. This raised the question whether

transfections could occur via the air.

When coughing, humans release thousands of aerosol droplets per cubic-centimeter in the

size range of 0.6 to 15 µm, with the droplet concentration increasing strongly with cough

flow rate [11]. But also normal breathing will lead to some aerosol production, which is

attributed to fluid film rupture in the respiratory bronchioles during inhalation leading to the

formation of droplets that are released during exhalation [12]. The size of these droplets is

mostly below 1 µm [13]. The mode of droplet generation implies that they consist of lung lining

liquid including dispersed viruses. Indeed, human volunteers exposed to virus-sized

nanoparticles show nano-scaled particles in their exhaled breath [14,15]. Also, the described

size distribution of particles emitted from coughing as well as normal respiration suggests

that an important proportion of them will be able to remain airborne for many hours in

turbulent conditions [16].

Objectives

This study aimed to estimate the cumulative viral load released from COVID-19 patients with

no to moderate symptoms in different aerosol sizes via respiration and coughing. We then

used this information to make a risk appraisal for the situation of a high emitter that is either

breathing normally or coughing in a room operated at different air exchange rates. We

chose a room size that is similar to a medical examination room or an office shared by two

to three people.

Design and Methods

Concept:

The release of viruses from individual patients was modeled by first calculating the viral load

per exhaled droplets formed during normal breathing and while coughing. The resulting size-

distribution provided an initial estimate of the concentration of SARS-CoV-2 virus copies

released by a regularly breathing or coughing patient. This viral emission factor was then fed

into a well-mixed one-compartment model to simulate the situation in a closed room with

different ventilation air exchange rates.

Data sources:

Data on the number of viral copies present in sputum was used to estimate the SARS-CoV-2

viral load present in the lining liquid of respiratory bronchioles in patients [9], specifically an

average of $7*10^6$ copies/ml with a maximum of $2.35*10^9$ copies/ml (hereafter referred to

as "high emitters"), and 1,000 copies/ml representing a low-virus producing patient ("low

emitters").

Exhaled aerosol size distributions and numbers were retrieved from published studies on

coughing [11] and healthy persons [12]. Both studies assessed the size-number distribution of

freshly emitted aerosols. The concentration of viral copies in each aerosol size was

calculated from the volume of the aerosols, the actual count number in each size and the

above-mentioned virus-load per ml sputum. The viral load in the actual aerosol counts in

each aerosol size was then used to calculate the total viral concentration. The cumulative

emissions in the PM_{10} fraction were summed up after applying the standard size

fractionation curves [17] to the aerosol distribution.

Model:

A one-compartment model estimated the virus load concentration C for a perfectly mixed

room of volume V_R of 50 m³ with one patient as source, using the following mass-balance

(equation 1):

$$V_R * \frac{dC}{dt} = c_{PM10} * RR * V_t - \frac{V_R}{ER} * C(t) - \frac{ln(2)*V_R}{t_{1/2}} * C(t) \qquad (1)$$

The emission rate was calculated from the concentration c_{PM10}, the viral load in the PM_{10}-

size range, which are particles collected with a 50% efficiency cut-off at 10 μm aerodynamic

diameter; and a respiratory rate of 15 breaths per minute (RR) at a tidal volume of V_t of 500

ml per breath. Air exchange rates (ER) used were 1-, 3-, 10- and 20-times per hour. The virus'

half-life $t_{1/2}$ of 1.1 hours was obtained from an experimental study about the persistence of

SARS-CoV-2 on surfaces and when airborne [18], tested by assessing the 50% tissue culture

infective dose ($TCID_{50}$).

The model for coughing was identical, except that coughing was assumed to happen every

30 seconds at a volume of 250 ml.

All statistics and models were calculated using Stata/SE 15.1 (Mac 64-bit Intel, Rev. 03 Feb

2020, StataCorp, College Station, TX, USA).

Results

Emissions from normal breathing patients

To estimate the virus emissions from patients breathing normally, we first calculated the

viral load for the aerosol size distribution. Figure 1 shows that the highest virus load is

present in the largest aerosol size. The cumulative total emission per breath was 0.34

copies/cm^3(air) for an average patient, and 11.5 copies/cm^3 for high emitters. The

cumulative emissions in the PM_{10} fraction were about 1/3 of these values with 0.12

copies/cm^3 (average) and 4.1 copies/cm^3 (high) per breath.

Emission from coughing patient

124   We then estimated the virus emissions from a coughing patient (Figure 2). The cumulative

125   total emission per cough was 19,400 copies/cm^3 for an average patient, and 651,315

126   copies/cm^3 for high emitters. The cumulative emissions in the PM_{10} fraction were about 1/2

127   of these values with 10,900 copies/cm^3 (average) and 366,000 copies/cm^3 (high) per cough.

Exposure estimation for bystanders

To estimate the exposure of bystanders spending time in the same room as a COVID-19

positive person, we calculated the time-course of the viral load in the thoracic size fraction

for aerosols released from a high-emitter either breathing normally or coughing. Figure 3

shows the results for a high-emitting patient coughing frequently.

For a typical hospital ventilation situation of 10 air exchanges per hour, the concentration

plateaus after about 30 minutes, while for a typical office with 3 air exchanges/hour,

concentrations continue to rise for almost three hours. In the used model, concentrations

scale linearly with the patient emission rate, the plateau concentrations for different

emitting patients and ventilation types are summarized in Table 1.

Discussion

An elevated number of viruses is expected to be released by COIVD-19 patients in the form

of airborne aerosols, especially when they are coughing. While the bigger portion of the

emitted viral load is in the form of large particles that can deposit rapidly, there is also an

important portion in the smaller size fractions. Small aerosols can remain airborne for an

extended time [16] and are very effective at reaching the deeper regions of the lungs.

An average person breathes about a half m^3 per hour in resting state [19], which can rapidly

increase to several m^3 during exercise [20]. Thus, a person spending time in a room with an

average emitting patient breathing normally has a realistic chance of inhaling tens to

hundreds of copies of the virus even when keeping distance from that person. The situation

is worse in the presence of a high emitter and worst if the patient is a coughing high emitter.

A review of a wide range of respiratory viruses suggests that the infective dose is often quite

low. Sometimes as few as few hundred units of active virus ($TCID_{50}$) [21] seem sufficient to

provoke a disease. Thus, our modelling suggests that there is a clear risk of infections for a

person spending an extended time in the room with an infected person, even if the distance

is too large for direct transmission. The situation is worse if the person is coughing.

The very high virus load in exhaled respiratory aerosols proposed by our assessment may be

an explanation why COVID-19 was associated with much more transfections to hospital staff

than what was expected from SARS [4]. While having everybody wear a surgical face mask can

be an effective source control [22], the protective factors may still be insufficient if an

extended amount of time is spent in the same room, especially if the room is small and the

ventilation low. Increasing ventilation can help to some extent but is not sufficient in a room

of the size of a typical office or medical exam room. Note also that ventilation design for

hospitals is complex and not always functioning as intended [23].

What are the implications for the normal life and the workplace?

• The risk of infection is real when being near an infected person in a room for more

than a few minutes and this even when keeping distance to that person.

• Sharing a workplace in a small room with a non-symptomatic case seems not

advised. This implies that workplaces should not be shared as long as there are no

rapid tests to differentiate between healthy and non-symptomatic cases.

• Medical staff is advised to wear the best possible respiratory protection whenever in

the same room as a patient, especially when this person is coughing.

• In addition, every patient, also non-symptomatic ones, should wear a well-fitting

surgical face mask to reduce emissions, which will increase the overall protection for

the medical staff.

Our assessment has a number of limitations. Namely:

• The estimated virus levels strongly depend on the number of virus copies produced

by a COVID-19 case. We used sputum data from a well described peer-reviewed

study [9] assuming that it is a reasonable approximation for the virus load in the

respiratory bronchioles, the space where most respiratory aerosols are formed. Our

high-emitter estimates would be 100-fold higher if the most extreme

correspondence data was used [10].

• We used information about virus copies but compare the results with $TCID_{50}$ infective

dose. Research on other virus types suggests that the number of virus copies and

$TCID_{50}$ are comparable [24]. However, it would be important to confirm this

relationship for the case of SARS-CoV-2.

• For breath aerosols release, we used data reported for normal breathing young

healthy subjects. However, aerosol formation is influenced by surface tension of the

lung lining liquid [25]. It is likely that aerosol formation will be altered in COVID-19

positive cases but it is not clear in which direction.

• Aerosol droplet will shrink in dry air [26], resulting in a shift to smaller particle sizes.

This will not directly change the number of copies in the PM_{10} range but simply

upconcentrate the viral load per aerosol. While we addressed passivation of viruses

in the air by using the documented half-life [18], it is still possible that viruses in smaller

droplets are quicker passivated because of shorter diffusion distances for airborne

oxidants and faster increasing salinity. Our estimates would be slightly smaller if this

was relevant.

Acknowledgments

196 This modelling was entirely funded by the Swiss Centre for Occupational and Environmental

197 Health (SCOEH).

References

- 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017

- 2. Gorbalenya AE, Baker SC, Baric RS, et al. *Severe Acute Respiratory Syndrome-Related Coronavirus: The Species and Its Viruses – a Statement of the Coronavirus Study Group*. Microbiology; 2020. doi:10.1101/2020.02.07.937862

- 3. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun*. March 2020:S0006291X20305234. doi:10.1016/j.bbrc.2020.03.044

- 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061. doi:10.1001/jama.2020.1585

- 5. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*. February 2020. doi:10.1001/jama.2020.2565

- 6. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(13):377-381. doi:10.15585/mmwr.mm6913e1

●　7.　　Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the

rapid dissemination of novel coronavirus (SARS-CoV2). *Science*. March 2020.

doi:10.1126/science.abb3221

●　8.　　Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory

Specimens of Infected Patients. *N Engl J Med*. 2020;382(12):1177-1179.

doi:10.1056/NEJMc2001737

●　9.　　Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of

hospitalized patients with COVID-2019. *Nature*. April 2020. doi:10.1038/s41586-020-

2196-x

●　10.　　Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical

samples. *Lancet Infect Dis*. 2020;20(4):411-412. doi:10.1016/S1473-3099(20)30113-4

●　11.　　Yang S, Lee GWM, Chen C-M, Wu C-C, Yu K-P. The Size and Concentration of

Droplets Generated by Coughing in Human Subjects. *J Aerosol Med*. 2007;20(4):484-

494. doi:10.1089/jam.2007.0610

●　12.　　Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. *J

Aerosol Med Pulm Drug Deliv*. 2009;22(3):229-237. doi:10.1089/jamp.2008.0720

●　13.　　Papineni RS, Rosenthal FS. The Size Distribution of Droplets in the Exhaled

Breath of Healthy Human Subjects. *J Aerosol Med*. 1997;10(2):105-116.

doi:10.1089/jam.1997.10.105

•   14.   Gschwind S, Graczyk H, Günther D, Riediker M. A method for the preservation

and determination of welding fume nanoparticles in exhaled breath condensate. *Env*

Sci Nano. 2016;3(2):357–364. doi:10.1039/C5EN00240K

•   15.   Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath

condensate as a matrix for combustion-based nanoparticle exposure and health effect

evaluation. *J Aerosol Med Pulm Drug Deliv*. 2014;27(6):449–458.

doi:10.1089/jamp.2013.1101

•   16.   Willeke K, Baron PA, eds. *Aerosol Measurement: Principles, Techniques, and*

Applications. New York: Van Nostrand Reinhold; 1993.

•   17.   BSI. *EN 481:1993 Workplace Atmospheres. Size Fraction Definitions for*

Measurement of Airborne Particles. BSI; 1993.

•   18.   van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability

of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. March

2020:NEJMc2004973. doi:10.1056/NEJMc2004973

•   19.   Beardsell I, ed. *Get through MCEM. Part A: MCQs*. London: RSM; 2011.

•   20.   Ramos CA, Reis JF, Almeida T, Alves F, Wolterbeek HT, Almeida SM. Estimating

the inhaled dose of pollutants during indoor physical activity. *Sci Total Environ*.

2015;527-528:111-118. doi:10.1016/j.scitotenv.2015.04.120

•   21.   Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory

and Enteric Viruses Transmitted Through Food and the Environment. *Food Environ*

Virol. 2011;3(1):1-30. doi:10.1007/s12560-011-9056-7

• 22. Patel RB, Skaria SD, Mansour MM, Smaldone GC. Respiratory source control

using a surgical mask: An *in vitro* study. *J Occup Environ Hyg*. 2016;13(7):569-576.

doi:10.1080/15459624.2015.1043050

• 23. Grosskopf KR, Herstein KR. The aerodynamic behavior of respiratory aerosols

within a general patient room. 2012;18(4):15.

• 24. Kim J-O, Kim W-S, Kim S-W, et al. Development and Application of

Quantitative Detection Method for Viral Hemorrhagic Septicemia Virus (VHSV)

Genogroup IVa. *Viruses*. 2014;6(5):2204-2213. doi:10.3390/v6052204

• 25. Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols.

Proc Natl Acad Sci. 2004;101(50):17383-17388. doi:10.1073/pnas.0408159101

• 26. Holmgren H, Bake B, Olin A-C, Ljungström E. Relation Between Humidity and

Size of Exhaled Particles. *J Aerosol Med Pulm Drug Deliv*. 2011;24(5):253-260.

doi:10.1089/jamp.2011.0880

Figure legends

Figure 1: Size distribution of exhaled aerosols (left) during normal respiration and resulting

viral emissions per breath (right) for average (red), high and low emitters (spike-lines) per

aerosol size.

Figure 2: Size distribution of exhaled aerosols (left) during coughing and resulting viral

emissions per breath (right) with average (red), high and low emitters (spike-lines) per

aerosol size.

Figure 3: Temporal course of airborne virus load in a perfectly mixed room of 50 m3 for

different air exchange rates. The emitter has a high virus-load in the lungs and is coughing

intermittently.

Tables

Table 1: Plateau concentration for different combinations of air exchange rate, emission form and emitter type.

Air exchange rate (times/ hour)	1 / hour	3 / hour	10 / hour	20 / hour
Time until 99% of plateau	169 minutes	77 minutes	26 minutes	14 minutes
	Airborne viral concentration at plateau (copies/m³)			
Regular breathing				
Low emitter	0.0096	0.0043	0.0015	0.0008
Average emitter	44.80	20.18	6.87	3.54
High emitter	22,554	10,100	3,458	1,782
Frequent coughing				
Low emitter	859	386	132	67.9
Average emitter	4,010,000	1,800,000	615,000	317,000
High emitter	2.02e+09	9.06e+08	3.10e+08	1.60e+08